Free Trial

Aligos Therapeutics (ALGS) SEC Filings & 10K Form

Aligos Therapeutics logo
$5.75 +0.39 (+7.28%)
As of 03:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Recent Aligos Therapeutics SEC Filings

DateFilerForm TypeView
04/03/2025
11:15 PM
Aligos Therapeutics (Filer)
Form EFFECT
04/03/2025
3:23 PM
Aligos Therapeutics (Filer)
Form 424B3
03/12/2025
7:30 PM
Aligos Therapeutics (Subject)
BLATT LAWRENCE (Filed by)
Form SCHEDULE 13D/A
03/10/2025
7:00 AM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/10/2025
7:07 AM
Aligos Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/12/2025
8:32 AM
Adage Capital Management, L.P. (Filed by)
Aligos Therapeutics (Subject)
Form SCHEDULE 13G/A
02/12/2025
7:52 AM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/03/2025
3:02 PM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/18/2024
11:15 PM
Aligos Therapeutics (Filer)
Form EFFECT
11/14/2024
5:57 PM
Aligos Therapeutics (Subject)
Vivo Capital Fund VIII, L.P. (Filed by)
Form SC 13G/A
11/14/2024
5:19 PM
Aligos Therapeutics (Subject)
EcoR1 Capital, LLC (Filed by)
Form SC 13G/A
11/14/2024
3:34 PM
Aligos Therapeutics (Subject)
HHLR ADVISORS, LTD. (Filed by)
Form SC 13G/A
11/12/2024
8:31 AM
Adage Capital Management, L.P. (Filed by)
Aligos Therapeutics (Subject)
Form SC 13G
11/06/2024
4:20 PM
Aligos Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
11/06/2024
4:14 PM
Aligos Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
11/06/2024
3:24 PM
Aligos Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2024
3:05 PM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/10/2024
3:16 PM
Achneck Hardean (Reporting)
Aligos Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/26/2024
3:15 PM
Achneck Hardean (Reporting)
Aligos Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
09/06/2024
3:22 PM
Aligos Therapeutics (Issuer)
Symons Julian A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/06/2024
3:23 PM
Aligos Therapeutics (Issuer)
BLATT LAWRENCE (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/06/2024
3:23 PM
Aligos Therapeutics (Issuer)
Calhoun Lesley Ann (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
3:06 PM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/19/2024
3:05 PM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2024
3:14 PM
Aligos Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/15/2024
4:01 PM
Aligos Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ALGS) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners